[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100341252":3},{"organization":4,"outcomesModule":7,"designInfo":7,"detailedDescription":8,"studyPopulation":7,"armGroups":7,"interventions":9,"overallOfficials":7,"centralContacts":16,"locations":22,"responsibleParty":36,"collaborators":38,"id":41,"slug":7,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Celgene","INDUSTRY",null,"This program is being offered on a patient by patient basis and will require company, Institutional Review Board\u002FIndependent Ethics Committee and Single Patient IND approval.",[10],{"type":11,"name":12,"description":13,"armGroupLabels":7,"otherNames":14},"DRUG","Oral Fedratinib","Oral fedratinib administered as directed by treating physician.",[15],"FEDR",[17],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Celgene Medical Information","CONTACT","1-888-771-0141","medinfo@celgene.com",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":7},"AVAILABLE","Summit","New Jersey","07901","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-74.36468,40.71562,{"lat":34,"lon":33},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[39],{"name":40,"class":6},"Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation","100341252",false,"NCT03723148","Individual Patient Compassionate Use of Fedratinib","Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib","Inclusion Criteria:\n\nSubjects will be considered if they received TG101348, SAR302503 or Fedratinib as a participant on a clinical trial prior to 31 Jan 2018.\n\nExclusion Criteria:\n\nSubject is eligible for enrollment in an ongoing clinical trial using Fedratinib or has been treated with Fedratinib after 31 Jan 2018.","ALL","18 Years","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib.\n\nExpanded access is only available in markets where fedratinib is not yet approved.",[52],"Myelofibrosis",[54,55],"Expanded Access","Compassionate Use","2020-09-17",{"date":58,"type":59},"2020-09-18","ACTUAL",{"name":5,"class":6},1]